Volume 148, Issue 4, Pages e8 (April 2015)

Slides:



Advertisements
Similar presentations
Efficacy of Obeticholic Acid in Patients with PBC and Inadequate Response to Ursodeoxycholic Acid Gastroenterology 2015, 148: Gideon M. Hirschfield,
Advertisements

Natural history of pruritus in primary biliary cirrhosis
Volume 143, Issue 3, Pages e1 (September 2012)
Volume 135, Issue 5, Pages (November 2008)
Volume 149, Issue 6, Pages e2 (November 2015)
Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study  Marjan de Vries, Dagmar C.M.
Volume 153, Issue 3, Pages e7 (September 2017)
Volume 145, Issue 3, Pages e1 (September 2013)
Abatacept for Crohn's Disease and Ulcerative Colitis
Covering the Cover Gastroenterology
Volume 153, Issue 3, Pages e7 (September 2017)
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical.
Volume 144, Issue 3, Pages e7 (March 2013)
Covering the Cover Gastroenterology
Section 7: Aggressive vs moderate approach to lipid lowering
Volume 147, Issue 6, Pages e5 (December 2014)
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
Pilot Study of Peripheral Muscle Function in Primary Biliary Cirrhosis: Potential Implications for Fatigue Pathogenesis  Kieren G. Hollingsworth, Julia.
Volume 154, Issue 1, Pages e6 (January 2018)
Volume 146, Issue 5, Pages e2 (May 2014)
Volume 149, Issue 6, Pages e2 (November 2015)
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists 
Volume 139, Issue 4, Pages (October 2010)
Covering the Cover Gastroenterology
Targeting the FXR Nuclear Receptor to Treat Liver Disease
Volume 149, Issue 6, Pages e2 (November 2015)
Volume 153, Issue 1, Pages e6 (July 2017)
Marina Cuchel, Dirk J. Blom, Maurizio R. Averna 
Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I  Ruben A. Mesa, Srdan Verstovsek,
Volume 143, Issue 5, Pages e2 (November 2012)
Volume 146, Issue 4, Pages e6 (April 2014)
Volume 155, Issue 6, Pages e5 (December 2018)
Volume 139, Issue 4, Pages e2 (October 2010)
Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis  Evan S. Dellon, David A. Katzka, Margaret.
Volume 130, Issue 2, Pages (February 2006)
Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment.
Volume 155, Issue 5, Pages e6 (November 2018)
Volume 136, Issue 4, Pages (April 2009)
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.
Volume 151, Issue 6, Pages (December 2016)
Volume 149, Issue 2, Pages e2 (August 2015)
Volume 149, Issue 7, Pages e2 (December 2015)
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir  Zobair.
Dietary Triggers of Abdominal Symptoms in Patients With Irritable Bowel Syndrome: Randomized Placebo-Controlled Evidence  Susan J. Shepherd, Francis C.
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.
Volume 151, Issue 1, Pages e6 (July 2016)
Volume 147, Issue 6, Pages e5 (December 2014)
Volume 132, Issue 1, Pages (January 2007)
Volume 146, Issue 1, Pages e3 (January 2014)
Volume 156, Issue 4, Pages e18 (March 2019)
Mark Topazian, Michael Camilleri, Felicity T. Enders, Jonathan E
Volume 152, Issue 4, Pages e5 (March 2017)
Volume 148, Issue 4, Pages e2 (April 2015)
Volume 70, Issue 3, Pages (March 2019)
Clinical Gastroenterology and Hepatology
Volume 156, Issue 1, Pages e5 (January 2019)
Volume 153, Issue 5, Pages e2 (November 2017)
Major classes of drugs to reduce lipids
Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C  Gowtham A. Rao, Prashant K. Pandya  Gastroenterology 
Covering the Cover Gastroenterology
Volume 143, Issue 3, Pages e1 (September 2012)
Volume 142, Issue 5, Pages e2 (May 2012)
Early Precut Sphincterotomy Does Not Increase Risk During Endoscopic Retrograde Cholangiopancreatography in Patients With Difficult Biliary Access: A.
Baby-Epsilon Steps Toward the Triple Aim
GS-9674 in NASH: a phase 2 study
Volume 139, Issue 6, Pages e1 (December 2010)
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.
Volume 153, Issue 3, Pages e2 (September 2017)
Natural history of pruritus in primary biliary cirrhosis
Volume 135, Issue 5, Pages (November 2008)
Presentation transcript:

Volume 148, Issue 4, Pages 751-761.e8 (April 2015) Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid  Gideon M. Hirschfield, Andrew Mason, Velimir Luketic, Keith Lindor, Stuart C. Gordon, Marlyn Mayo, Kris V. Kowdley, Catherine Vincent, Henry C. Bodhenheimer, Albert Parés, Michael Trauner, Hanns-Ulrich Marschall, Luciano Adorini, Cathi Sciacca, Tessa Beecher-Jones, Erin Castelloe, Olaf Böhm, David Shapiro  Gastroenterology  Volume 148, Issue 4, Pages 751-761.e8 (April 2015) DOI: 10.1053/j.gastro.2014.12.005 Copyright © 2015 AGA Institute Terms and Conditions

Figure 1 (A) Mean ± SD ALP relative change from baseline to end of study in the mITT (last observation carried forward) population. P < .0001 pair-wise comparison for all treatment groups. (B) Percent decrease in ALP values in the completer population. Pairwise comparisons for 10%, 20% and 40% cutoff, respectively: 10 mg P < .0001, P < .0001, P = .0031; 25 mg P < .0001, P < .0001, P = .0272; 50 mg P < .000l for all cutoffs, respectively. P value: Comparison of proportion of patients with a 10%, 20%, 40%, or complete response for OCA dose groups with placebo group using the likelihood ratio χ2 test. ∗∗P < .05; ∗∗∗P < .0001. Gastroenterology 2015 148, 751-761.e8DOI: (10.1053/j.gastro.2014.12.005) Copyright © 2015 AGA Institute Terms and Conditions

Figure 2 OCA treatment decreases serum ALP levels in patients with PBC in the double-blind (DB) trial and the open-label extension. (A) Decreases in ALP values during the DB phase were significant for all OCA dose groups vs placebo at all the study day visits (P < .0001). After OCA withdrawal on day 85, mean ALP values started to increase, but 2 weeks later had not reached mean baseline ALP values and remained statistically lower compared with the placebo group. ALP values in the completer population in the DB trial. P < .0001 for all OCA dose groups vs placebo. (B) Change in ALP values in the completer population in the DB trial. P < .0001 for all OCA dose groups vs placebo. (C) Decreases in ALP values during the open-label extension trial were significant for all OCA dose groups vs placebo at all the study day visits (P < .0001). (D) Change in ALP values during the open-label extension trial for the completer population. P < .0001 for all OCA dose groups vs placebo at all the study day visits. ∗P < .01; ∗∗P < .001; ∗∗∗P < .0001. Gastroenterology 2015 148, 751-761.e8DOI: (10.1053/j.gastro.2014.12.005) Copyright © 2015 AGA Institute Terms and Conditions

Figure 3 OCA treatment increases FGF19 and decreases C4 and endogenous BA plasma levels. Increased FGF19 (A), associated with decreased C4 (B), and endogenous BA (C) plasma levels in PBC patients after OCA treatment. Data are presented as median (line in middle of box), interquartile range (top and bottom of box), minimum and maximum (outliers denoted by diamonds). Statistical significance is based on the change from baseline to end of treatment. After treatments with 10 mg, 25 mg, and 50 mg OCA, changes in FGF19 levels (P = .0007; P < .0001; P = .002), C4 (P = .0275; P < .0001; P < .0003), and BA (P = .0093; P < .0001; P < .0001) were all respectively significant. Gastroenterology 2015 148, 751-761.e8DOI: (10.1053/j.gastro.2014.12.005) Copyright © 2015 AGA Institute Terms and Conditions

Figure 4 Pruritus severity in PBC patients expressed as percent of patients with mild, moderate, or severe pruritus. (A) Pruritus severity in the double-blind phase. (B) Pruritus severity in the open-label OCA therapy extension. Gastroenterology 2015 148, 751-761.e8DOI: (10.1053/j.gastro.2014.12.005) Copyright © 2015 AGA Institute Terms and Conditions

Supplementary Figure 1 Patient disposition. Gastroenterology 2015 148, 751-761.e8DOI: (10.1053/j.gastro.2014.12.005) Copyright © 2015 AGA Institute Terms and Conditions

Supplementary Figure 2 Dose-titration effect of OCA therapy in the open-label extension. Panel A compares the effect of OCA at 10 mg and 25 mg daily; panel B compares the effect of OCA at 25 mg and 50 mg daily. ALP values are presented as mean ± SD percent change from baseline after a 30-day pre-titration (gray bars) and 30-day post-titration (black bars) dosing. ∗∗P = .01 for relative change from baseline compared with placebo. Gastroenterology 2015 148, 751-761.e8DOI: (10.1053/j.gastro.2014.12.005) Copyright © 2015 AGA Institute Terms and Conditions

Supplementary Figure 3 Safety population. Persistent biochemical response in PBC patients after OCA therapy in the open-label extension. Patients on OCA therapy in the OLE demonstrated sustained reduction compared with baseline in GGT (A), ALT (B), and AST (C) levels 1 year after treatment initiation. ∗∗ P < .001 and ∗∗∗ P < .0001 (transaminases and GGT, all time points) vs time 0. Data are mean ± SD. Gastroenterology 2015 148, 751-761.e8DOI: (10.1053/j.gastro.2014.12.005) Copyright © 2015 AGA Institute Terms and Conditions

Supplementary Figure 4 Mean absolute levels of (A) low-density lipoprotein (LDL) and (B) high-density lipoprotein (HDL) and over time. Data are mean values for safety population. Gastroenterology 2015 148, 751-761.e8DOI: (10.1053/j.gastro.2014.12.005) Copyright © 2015 AGA Institute Terms and Conditions